AIGH Capital Management LLC Has $14.50 Million Stock Position in Castle Biosciences, Inc. $CSTL

AIGH Capital Management LLC lessened its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 590,601 shares of the company’s stock after selling 34,118 shares during the quarter. Castle Biosciences comprises 2.0% of AIGH Capital Management LLC’s investment portfolio, making the stock its 11th biggest position. AIGH Capital Management LLC owned 1.95% of Castle Biosciences worth $14,499,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of CSTL. Amundi grew its stake in Castle Biosciences by 15,811.5% during the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Castle Biosciences by 548.9% in the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after buying an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Castle Biosciences by 34.7% in the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after acquiring an additional 8,992 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Roth Capital began coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective for the company. Weiss Ratings lowered Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Canaccord Genuity Group lowered their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, April 20th. KeyCorp set a $35.00 price objective on Castle Biosciences in a research report on Friday, May 29th. Finally, Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Castle Biosciences has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL opened at $23.64 on Thursday. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. The company has a market cap of $717.00 million, a price-to-earnings ratio of -53.73 and a beta of 1.00. The firm has a 50 day simple moving average of $21.51 and a 200 day simple moving average of $28.24.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). The firm had revenue of $84.23 million for the quarter, compared to analysts’ expectations of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. Research analysts predict that Castle Biosciences, Inc. will post -1.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 8,586 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total value of $209,670.12. Following the completion of the transaction, the chief operating officer owned 21,874 shares of the company’s stock, valued at $534,163.08. This represents a 28.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 3,622 shares of Castle Biosciences stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $87,978.38. Following the sale, the insider directly owned 12,368 shares in the company, valued at $300,418.72. The trade was a 22.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 49,361 shares of company stock worth $1,119,278 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.